1,104,274 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Purchased by Sofinnova Investments Inc.

Sofinnova Investments Inc. acquired a new stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,104,274 shares of the company’s stock, valued at approximately $27,618,000. Centessa Pharmaceuticals comprises about 1.1% of Sofinnova Investments Inc.’s investment portfolio, making the stock its 29th biggest holding. Sofinnova Investments Inc. owned approximately 0.82% of Centessa Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the business. Spruce Street Capital LP bought a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at about $1,951,000. Aigen Investment Management LP bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth approximately $314,000. Maverick Capital Ltd. bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth approximately $41,110,000. Marshall Wace LLP boosted its stake in Centessa Pharmaceuticals by 90.3% in the fourth quarter. Marshall Wace LLP now owns 216,130 shares of the company’s stock worth $5,405,000 after buying an additional 102,540 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in Centessa Pharmaceuticals in the fourth quarter worth approximately $11,033,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Lifesci Capital lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Wells Fargo & Company lowered Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $35.00 to $42.00 in a research note on Monday, April 20th. Needham & Company LLC lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Stephens downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Finally, B. Riley Financial downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Four research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $39.76 on Tuesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $12.05 and a 1 year high of $40.26. The stock’s 50 day simple moving average is $39.64 and its two-hundred day simple moving average is $30.96. The company has a market cap of $6.15 billion, a price-to-earnings ratio of -22.21 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). As a group, equities analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Karen M. Anderson sold 41,076 shares of the stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the sale, the insider owned 62,085 shares in the company, valued at approximately $1,870,000.20. This represents a 39.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.09% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.